The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells
Abstract
Previous studies demonstrated that intermittent treatment with PTH increases osteoblast number and bone formation in growing and adult rats. The cellular mechanism for this increase in osteoblast number was investigated in 16-month-old female rats. Continuous [3H]thymidine infusion over a 1-week intermittent PTH [human PTH-(1-34)] treatment period was performed to determine the percentage of newly formed osteoblasts that originate from progenitor cells. To verify increases in bone formation, we performed histomorphometry and Northern blot analysis of selected bone matrix proteins. PTH treatment resulted in dramatic increases in fluorochrome-labeled perimeter (727%), osteoid perimeter (735%), osteoblast number (626%), and steady state mRNA levels of osteocalcin (946%) and type 1 collagen (> 1000%). Autoradiographic analysis of metaphyseal sections revealed no difference in the percentage of [3H]thymidine-labeled osteoblasts between PTH- and vehicle-treated groups (4.3 +/- 1.3% vs. 5.7 +/- 2.7%, respectively). Similar changes were observed in PTH-treated ovariectomized rats. As the PTH-induced increase in osteoblast number did not require proliferation of progenitor cells we carried out an additional experiment in adult ovariectomized rats to determine the onset of PTH action. Incorporation of [3H]proline in the distal femoral epiphysis of PTH-treated adult ovariectomized rats was increased within 24 h. We conclude that the rapid PTH-induced rise in bone formation did not require cell proliferation and was most likely due to activation of preexisting bone lining cells to osteoblasts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anabolic Actions of Parathyroid Hormone on Bone*
DEMPSTER, D. W., COSMAN, F., PARISIEN, M., SHEN, V., & LINDSAY, R. (1993) · Endocrine Reviews · doi:10.1210/edrv-14-6-690 · Cited by 717
The effects of raloxifene on tibia histomorphometry in ovariectomized rats
Evans, G. L. (1994) · Endocrinology · doi:10.1210/en.134.5.2283 · Cited by 142
Cited by
Dempster, D. W., Compston, J. E., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., Recker, R. R., & Parfitt, A. M. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1805 · Cited by 2,543
“Lining cells are of osteoblast lineage and are thought to have osteogenic potential.((17)) The term ‘‘osteoclast’’ is restricted to bone-resorbing cells containing lysosomes and tartrate-resistant acid phosphatase; they are usually multinucleated, although some osteoclast profiles may have only one or no nucleus.”
BackgroundManolagas, S. C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0395 · Cited by 2,568
Normal Bone Anatomy and Physiology
Clarke, B. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04151206 · Cited by 2,192
“Bone-lining cells may regulate influx and efflux of mineral ions into and out of bone extracellular fluid, thereby serving as a blood-bone barrier, but retain the ability to redifferentiate into osteoblasts upon exposure to parathyroid hormone or mechanical forces (25).”
BackgroundTherapeutic Approaches to Bone Diseases
Rodan, G. A., & Martin, T. J. (2000) · Science · doi:10.1126/science.289.5484.1508 · Cited by 1,767
Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M., & Manolagas, S. C. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6610 · Cited by 1,043
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH
Jilka, R. L. (2007) · Bone · doi:10.1016/j.bone.2007.03.017 · Cited by 720
Vahle, J. L., Sato, M., Long, G. G., Young, J. K., Francis, P. C., Engelhardt, J. A., Westmore, M. S., Ma, Y. L., & Nold, J. B. (2002) · Toxicologic Pathology · doi:10.1080/01926230252929882 · Cited by 695
Osteoclast-derived activity in the coupling of bone formation to resorption
Martin, T. J., & Sims, N. A. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.12.004 · Cited by 659
SOST is a target gene for PTH in bone
Keller, H., & Kneissel, M. (2005) · Bone · doi:10.1016/j.bone.2005.03.018 · Cited by 616
Parathyroid hormone: anabolic and catabolic actions on the skeleton
Silva, B. C., & Bilezikian, J. P. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.03.005 · Cited by 557
Physiological Bone Remodeling: Systemic Regulation and Growth Factor Involvement
Siddiqui, J. A., & Partridge, N. C. (2016) · Physiology · doi:10.1152/physiol.00061.2014 · Cited by 534
Sims, N. A., & Gooi, J. H. (2008) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.07.016 · Cited by 513
Saag, K. G., Zanchetta, J. R., Devogelaer, J., Adler, R. A., Eastell, R., See, K., Krege, J. H., Krohn, K., & Warner, M. R. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24879 · Cited by 493
“10 Biomechanical markers of bone turnover, median (25th, 75th percentiles)** Bone ALP, g/liter 9 (7, 12) 9 (6, 11) OC, g/liter 14 (10, 19) 14 (9, 19) PICP, g/liter 140 (111, 177) 148 (122, 183) PINP, g/liter 39 (29, 51) 39 (29, 57) CTX, pmoles/liter 3,331 (2,388, 5,366) 3,378 (2,050, 4,732) Disorders requiring glucoco…”
BackgroundDifferential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate
Ettinger, B., Martin, S. J., Crans, G., & Pavo, I. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040117 · Cited by 487
Advances in the osteoblast lineage
Aubin, J. E. (1998) · Biochemistry and Cell Biology · doi:10.1139/bcb-76-6-899 · Cited by 444
Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
Ke, H. Z., Richards, W. G., Li, X., & Ominsky, M. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1060 · Cited by 402
Hauge, E. M., Qvesel, D., Eriksen, E. F., Mosekilde, L., & Melsen, F. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.9.1575 · Cited by 397
Riggs, B. L., & Parfitt, A. M. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041114 · Cited by 380
Bellido, T., Ali, A. A., Plotkin, L. I., Fu, Q., Gubrij, I., Roberson, P. K., Weinstein, R. S., O'Brien, C. A., Manolagas, S. C., & Jilka, R. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307444200 · Cited by 378
Borer, K. T. (2005) · Sports Medicine · doi:10.2165/00007256-200535090-00004 · Cited by 373
Beyond Desensitization: Physiological Relevance of Arrestin-Dependent Signaling
Luttrell, L. M., Gesty-Palmer, D., & Sibley, D. R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002436 · Cited by 369
Body, J.-J., Gaich, G. A., Scheele, W. H., Kulkarni, P. M., Miller, P. D., Peretz, A., Dore, R. K., Correa-Rotter, R., Papaioannou, A., Cumming, D. C., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020334 · Cited by 365
Cosman, F., Eriksen, E. F., Recknor, C., Miller, P. D., Guañabens, N., Kasperk, C., Papanastasiou, P., Readie, A., Rao, H., Gasser, J. A., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.238 · Cited by 359
Building bone to reverse osteoporosis and repair fractures
Khosla, S., Westendorf, J. J., & Oursler, M. J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33612 · Cited by 353
Ishizuya, T., Yokose, S., Hori, M., Noda, T., Suda, T., Yoshiki, S., & Yamaguchi, A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119491 · Cited by 349
Parathyroid hormone-dependent signaling pathways regulating genes in bone cells
Swarthout, J. T., D'Alonzo, R. C., Selvamurugan, N., & Partridge, N. C. (2002) · Gene · doi:10.1016/s0378-1119(01)00798-3 · Cited by 340
Dobnig, H. (1997) · Endocrinology · doi:10.1210/en.138.11.4607 · Cited by 322
Self-citationCosman, F., Nieves, J., Woelfert, L., Formica, C., Gordon, S., Shen, V., & Lindsay, R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.5.925 · Cited by 311
A mechanosensitive peri-arteriolar niche for osteogenesis and lymphopoiesis
Shen, B., Tasdogan, A., Ubellacker, J. M., Zhang, J., Nosyreva, E. D., Du, L., Murphy, M. M., Hu, S., Yi, Y., Kara, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03298-5 · Cited by 310
A theoretical framework for strain-related trabecular bone maintenance and adaptation
Ruimerman, R., Hilbers, P., van Rietbergen, B., & Huiskes, R. (2005) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2004.03.037 · Cited by 300
Hormones and Disorders of Mineral Metabolism
Bringhurst, F. R., Demay, M. B., & Kronenberg, H. M. (2011) · Williams Textbook of Endocrinology · doi:10.1016/b978-1-4377-0324-5.00028-6 · Cited by 298
PTH and PTHrP signaling in osteoblasts
Datta, N. S., & Abou-Samra, A. B. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.02.012 · Cited by 295
The role of osteoblasts in energy homeostasis
Dirckx, N., Moorer, M. C., Clemens, T. L., & Riddle, R. C. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0246-y · Cited by 292
Lindsay, R., Cosman, F., Zhou, H., Bostrom, M. P., Shen, V. W., Cruz, J. D., Nieves, J. W., & Dempster, D. W. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051109 · Cited by 277
Kim, S. W., Pajevic, P. D., Selig, M., Barry, K. J., Yang, J.-Y., Shin, C. S., Baek, W.-Y., Kim, J.-E., & Kronenberg, H. M. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1665 · Cited by 266
Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned
Drake, M. T., Clarke, B. L., Oursler, M. J., & Khosla, S. (2017) · Endocrine Reviews · doi:10.1210/er.2015-1114 · Cited by 266
Parathyroid hormone: a double-edged sword for bone metabolism
Qin, L., Raggatt, L. J., & Partridge, N. C. (2004) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2004.01.006 · Cited by 263
Bikle, D. D., Sakata, T., Leary, C., Elalieh, H., Ginzinger, D., Rosen, C. J., Beamer, W., Majumdar, S., & Halloran, B. P. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.9.1570 · Cited by 259
Weitzmann, M. N. (2013) · Scientifica · doi:10.1155/2013/125705 · Cited by 259
Quiescent Bone Lining Cells Are a Major Source of Osteoblasts During Adulthood
Matic, I., Matthews, B. G., Wang, X., Dyment, N. A., Worthley, D. L., Rowe, D. W., Grcevic, D., & Kalajzic, I. (2016) · Stem Cells · doi:10.1002/stem.2474 · Cited by 195
The Bone Remodeling Compartment: A Circulatory Function for Bone Lining Cells
Parfitt, A. M. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.9.1583 · Cited by 169
Chung, D. J., Castro, C. H. M., Watkins, M., Stains, J. P., Chung, M. Y., Szejnfeld, V. L., Willecke, K., Theis, M., & Civitelli, R. (2006) · Journal of Cell Science · doi:10.1242/jcs.03162 · Cited by 169
“Although earlier studies indicated that intermittent PTH administration activates existing bone lining cells without affecting cell proliferation (Dobnig and Turner, 1995), an increase in bone marrow osteoprogenitor cells has been reported in response to PTH in rats (Kostenuik et al., 1999) and…”
BackgroundOminsky, M. S., Niu, Q.-T., Li, C., Li, X., & Ke, H. Z. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2152 · Cited by 167
Saini, V., Marengi, D. A., Barry, K. J., Fulzele, K. S., Heiden, E., Liu, X., Dedic, C., Maeda, A., Lotinun, S., Baron, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.441360 · Cited by 167
Re-thinking the bone remodeling cycle mechanism and the origin of bone loss
Delaisse, J.-M., Andersen, T. L., Kristensen, H. B., Jensen, P. R., Andreasen, C. M., & Søe, K. (2020) · Bone · doi:10.1016/j.bone.2020.115628 · Cited by 152
Kostenuik, P. J., Harris, J., Halloran, B. P., Turner, R. T., Morey-Holton, E. R., & Bikle, D. D. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.1.21 · Cited by 119
Gooi, J. H., Pompolo, S., Karsdal, M. A., Kulkarni, N. H., Kalajzic, I., McAhren, S. H. M., Han, B., Onyia, J. E., Ho, P. W. M., Gillespie, M. T., et al. (2010) · Bone · doi:10.1016/j.bone.2010.02.018 · Cited by 117
“proposed to explain the PTH anabolic effect, including direct actions favoring committed osteoblast precursor differentiation [3], inhibition of osteoblast apoptosis [4], and more recently, reduced production of the osteocyte-derived anti-anabolic agent sclerostin [5, 6].”
BackgroundOminsky, M. S., Brown, D. L., Van, G., Cordover, D., Pacheco, E., Frazier, E., Cherepow, L., Higgins-Garn, M., Aguirre, J. I., Wronski, T. J., et al. (2015) · Bone · doi:10.1016/j.bone.2015.08.007 · Cited by 93
Samadfam, R., Xia, Q., & Goltzman, D. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060915 · Cited by 80
Halloran, B. P., Bikle, D. D., Harris, J., Tanner, S., Curren, T., & Morey-Holton, E. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.7.1068 · Cited by 45
New Insights into Calorie Restriction Induced Bone Loss
Liu, L., & Rosen, C. J. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.1673 · Cited by 25
“For bone formation, PTH could increase osteoblast numbers and promote osteoblast activity [86-88].”
Background
Metadata
- Authors
- Dobnig, H.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 1995-08-01
- Volume
- 136
- Issue
- 8
- Pages
- 3632-3638
- ISSN
- 0013-7227 (ISSN-L)
- OpenAlex
- W2066342271
- Cited by
- 615
- References
- 2
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.